Amino-quinoxaline and amino-quinoline compounds for use as adenosine A
View Patent ↗Compounds of the Formula (I), where W represents CH or N; and Q represents —CN, —C(═NOH)NH 2 , —CONHR 1 or various herein described heterocyclic radicals; as well as pharmaceutically acceptable salts, solvates, esters and prodrugs thereof are adenosine A 2a receptor antagonists and, therefore, are useful in the treatment of central nervous system diseases, in particular Parkinson's disease.
1. A compound of the structural Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
Z is independently hydrogen, halogen or haloalkyl;
Q is —CONHR 1 ; or is a heterocyclic radical selected from the group consisting of:
R 1 is aralkyl, aryloxyalkyl, benzocycloalkyl or heteroarylalkyl; and
R 2 is amino, aryl, heteroaryl, arylamino, arylalkyl or heteroarylalkyl.
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Q is a heterocyclic radical of the formula:
wherein R 2 is amino, aryl, heteroaryl, arylamino, arylalkyl or heteroarylalkyl.
3. A compound of the structure:
or a pharmaceutically acceptable salt thereof, wherein:
Z is independently hydrogen, halogen or haloalkyl;
Q is independently —CONHR 1 or a heterocyclic radical of the formula:
wherein:
R 1 is aralkyl, benzocycloalkyl or heteroarylalkyl; and
R 2 is aryl, heteroaryl or arylalkyl.
4. The compound of claim 3 , or a pharmaceutically acceptable salt thereof, wherein Q is —CONHR 1 .
5. A pharmaceutical composition comprising at least one compound of claim 3 , or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier, adjuvant or vehicle.
6. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
7. A pharmaceutical composition comprising at least one compound of claim 6 , or a pharmaceutically acceptable salt-thereof and at least one pharmaceutically acceptable carrier, adjuvant or vehicle.